While our findings are consistent with earlier work showing that tau PET outperformed MRI in differentiating AD from non-AD disorders,9 the present study is, to our knowledge, the first to report findings from a large number of individuals using a second-generation tau tracer and directly compare the diagnostic performance of tau PET, MRI, and CSF markers for AD vs other neurodegenerative disorders. The gene discussed is MAPT; the disease is Alzheimer disease.